Menu Search
Equities

Inhibrx Biosciences Inc

G0S:BER

Inhibrx Biosciences Inc

Actions
  • Price (EUR)0.00
  • Today's Change0.00 / --
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of May 30 2024 07:30 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Inhibrx Biosciences Inc's revenues fell -17.88% from 2.19m to 1.80m. a loss of 145.23m to a larger loss of 241.36m.
Gross margin--
Net profit margin88,264.55%
Operating margin89,188.29%
Return on assets693.63%
Return on equity1,679.65%
Return on investment815.31%
More ▼

Cash flow in USDView more

In 2023, Inhibrx Biosciences Inc did not generate a significant amount of cash. Cash Flow from Financing totalled 201.96m or 11,220.06% of revenues. In addition the company used 193.31m for operations while cash used for investing totalled 4.59m.
Cash flow per share38.38
Price/Cash flow per share0.1434
Book value per share15.15
Tangible book value per share15.15
More ▼

Balance sheet in USDView more

Inhibrx Biosciences Inc appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio6.20
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.